Skip to main content
Top
Literature
go back to reference Baum, M., Budzar, A., Cuzick, J., Forbes, J., Houghton, J., Klijn, J.,et al. (2001). The ATAC (Arimidex, Tamoxifen, Alone, or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women. Paper presented at the 24th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas. Baum, M., Budzar, A., Cuzick, J., Forbes, J., Houghton, J., Klijn, J.,et al. (2001). The ATAC (Arimidex, Tamoxifen, Alone, or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women. Paper presented at the 24th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas.
go back to reference Ellis, M., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Janicke, F.,et al. (2001). Letrozole is more effective neoadjuvant endocrine therapy than Tamoxifen for ErbB-1 - and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol, 19(18), 3808–3816.PubMed Ellis, M., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Janicke, F.,et al. (2001). Letrozole is more effective neoadjuvant endocrine therapy than Tamoxifen for ErbB-1 - and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol, 19(18), 3808–3816.PubMed
go back to reference Lipton, A., Ali, S., Leitzel, K., Demers, L., Chinchilli, V., Engle, L.,et al. (2002). Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatis breast cancer. J Clin Oncol, 20(6), 1467–1472.PubMedCrossRef Lipton, A., Ali, S., Leitzel, K., Demers, L., Chinchilli, V., Engle, L.,et al. (2002). Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatis breast cancer. J Clin Oncol, 20(6), 1467–1472.PubMedCrossRef
go back to reference Osborne, C., Bardou, V., Hopp, T., Chamness, G., Hilsenbeck, S., Fuqua, S.,et al. (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst, 95(5), 353–361.PubMedCrossRef Osborne, C., Bardou, V., Hopp, T., Chamness, G., Hilsenbeck, S., Fuqua, S.,et al. (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst, 95(5), 353–361.PubMedCrossRef
go back to reference Veach, P., Bartels, D., & LeRoy, B. (2002). Defining moments: Catalysts for professional development. J. Genet Counseling, 11(4), 277–280.CrossRef Veach, P., Bartels, D., & LeRoy, B. (2002). Defining moments: Catalysts for professional development. J. Genet Counseling, 11(4), 277–280.CrossRef
Metadata
Title
Becoming a Daughter
Author
Ellen T. Matloff
Publication date
01-06-2006
Publisher
Springer US
Published in
Journal of Genetic Counseling / Issue 3/2006
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-005-9012-5

Other articles of this Issue 3/2006

Journal of Genetic Counseling 3/2006 Go to the issue